qfx

AI Writes Code, Humans Lose Jobs, and Other Tales of Woe 😅

by

In a dispatch posted on X-the platform formerly known as Twitter but now apparently christened “X” because why not?-Armstrong assured us all that this AI business would be handled responsibly. “Obviously,” he declared, in tones one imagines were suitably grave, “it needs to be reviewed and understood.” How reassuring! One pictures him stroking an invisible beard while nodding sagely. He went so far as to share a chart demonstrating how AI-generated code has more than doubled since April, which is either impressive or alarming depending on whether you’re an optimist or someone who fears Skynet is just around the corner.

Dividends Beneath the Ruins: Pfizer and Bristol Myers Squibb

by

Pfizer, once the paragon of pharmaceutical prowess, has endured its share of indignities. Its recent past reads like the diary of an overtaxed aristocrat: revenue streams drying up, patent cliffs looming ominously, and investors fretting about the future of blockbusters like Eliquis. Yet, like a dowager countess who discovers she still possesses a few jewels hidden in her reticule, Pfizer has begun to rally.

Binance’s BTC Futures: Bull Run or Bust? 🚀

by

According to crypto analyst Arab Chain, Binance’s total futures volume for August reached $2.626 trillion, an all-time high for 2025. This figure surpasses the previous record of $2.552 trillion set in July, reflecting a powerful return of market momentum and a fresh influx of capital. The analyst points to strengthened liquidity on Binance, which is solidifying its position as a dominant global futures marketplace. “Aha! The market is alive, but is it wise?” 🤔

Profit Amid Panic: Two AI Titans on Sale

by

Let us not mourn these fallen angels. Let us sharpen our checklists and polish our wallets. When Wall Street suffers a collective nervous breakdown, the prudent investor hears not screams, but violins playing a waltz of opportunity.

The Unappetizing Truth About Pfizer’s Dividends

by

Pfizer, of course, is a pharmaceutical giant, which means that the drugs it manufactures are as complicated as the finest French pastries. Years of research, trials, and regulatory approval are required before the company can launch a product-an arduous process that invites a certain protectionist benevolence from the government in the form of patent monopolies. How kind of them, really. Yet these monopolies, like all monopolies, are temporary. And when that magic period expires, the competition-like a swarm of eager locusts-descends with cheaper generics. The inevitable “patent cliff,” one might call it, is fast approaching, and naturally, investors have been abuzz with concern. How quaint.

15 Actresses Perfect for the Role of the Jubilee in the MCU

by

This list features actors who have demonstrated strong on-screen charisma, specializing in action or dance, and a diverse portfolio that spans both comedy and drama. Each actor has a recent project that demonstrates consistent growth in their career and a flexible schedule suitable for a long-running franchise.

Ulysse Nardin Unveils the Freak [X Crystalium] With a Shimmering Dial

by

At the Geneva Watch Days 2025, Ulysse Nardin unveiled the Freak [X Crystalium], a groundbreaking blend of mechanical ingenuity and advanced artistic decoration. Available in only 50 pieces globally, this version expands the boundaries of the Freak collection by merging its iconic one-hour orbiting carousel with an unprecedented hour display material. Instead of a conventional dial and hands, a rotating Crystalium disc takes center stage, featuring intricate fractal patterns crafted using ruthenium and a unique vapor-deposition crystallization process. Each piece is a unique, ruthenium-based art creation.

The Redemption of Steel and Fire: Stellantis’ Descent and the Phantom of Hope

by

To confess error-a act as unnatural to boardrooms as milk to a vampire-is the first trembling step toward absolution. Filosa’s admission, though not born of his own sin, is a lantern in the fog. For Stellantis, a colossus teetering on rusted legs, the path forward demands more than mechanical recalibration. It requires the resurrection of the Jeep Cherokee-a ghost from the graveyard of discontinued models-to rise not merely as a vehicle, but as a sacrament of rebirth.